Zymeworks ( (ZYME) ) has shared an announcement.
Zymeworks Inc. announced its participation in upcoming investor conferences, including the Needham 24th Annual Virtual Healthcare Conference and the Stifel 2025 Virtual Targeted Oncology Forum. These engagements highlight Zymeworks’ efforts to engage with investors and stakeholders, potentially impacting its industry positioning and stakeholder relations. The company’s ongoing advancements in its therapeutic pipeline, including the regulatory review of zanidatamab in the EU and China, and the active recruitment for Phase 1 studies of new candidates, underscore its commitment to addressing unmet medical needs.
More about Zymeworks
Zymeworks Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company aims to improve the standard of care for difficult-to-treat diseases such as cancer, inflammation, and autoimmune diseases. Zymeworks utilizes its proprietary Azymetric™ technology to engineer and develop differentiated antibody-based therapeutic candidates, including zanidatamab, a HER2-targeted bispecific antibody. The company has established strategic partnerships with BeiGene, Ltd. and Jazz Pharmaceuticals for the development and commercialization of zanidatamab in different territories.
YTD Price Performance: -13.40%
Average Trading Volume: 524,239
Technical Sentiment Signal: Sell
Current Market Cap: $897.9M
Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.